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Tail suspension testThe compound 2-(2-benzofuranyl)-2-imidazoline (2-BFI) is a 2-imidazoline derivative that selectively in-
hibits the in vitro activity of monoamine oxidase-A and it is also an imidazoline I2 agonist. However, the an-
tidepressant potential of this compound and its mechanism of action have not been well deﬁned. Therefore,
in this study we investigated the antidepressant-like effect of 2-BFI in mice. 2-BFI (100 and 300 μmol/kg, s.c.)
signiﬁcantly reduced the immobility time on the tail suspension test (TST) without changing locomotion in
the open ﬁeld test. The reduced the immobility time of 2-BFI (100 μmol/kg, s.c.) was conﬁrmed with the
forced swimming test (FST). The antidepressant-like effect of 2-BFI (100 μmol/kg, s.c.) in the TST was pre-
vented by pretreatment with idazoxan (0.4 μmol/kg, i.p., a I2 site antagonist), methysergide (4 μmol/kg,
i.p., a non-selective serotonergic receptor antagonist) and haloperidol (0.1 μmol/kg, i.p., a non-selective do-
paminergic receptor antagonist). The anxiolytic effect of 2-BFI was also evaluated, using the elevated plus-
maze test. 2-BFI (300 μmol/kg, s.c.) was able to signiﬁcantly increase the % of number of entries and the %
of time spent in the open arms, indicating that it possesses an anxiolytic effect at high doses. In conclusion,
these results suggest that the antidepressant-like effect of 2-BFI might involve serotonergic, dopaminergic
and imidazoline systems, and then the imidazoline site could represent a new pharmacological target for
the treatment of depression.
© 2011 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
The existence of non-adrenoceptor binding sites for imidazo-
l(ine)/guanidine drugs has been shown in various tissues of several
species, including the central nervous system (Eglen et al., 1998;
Regunathan and Reis, 1996). Such sites have been separated into at
least three entities: the I1 site, which is found in the brainstem and
is associated with blood pressure control (Bousquet et al., 1984);
the I2 site that is predominantly found in the brain and liver, where
it regulates monoamine turnover (Alemany et al., 1997); and the I3
site, that is located in pancreatic β-cells and regulates insulin secre-
tion (Chan et al., 1994)., 2-(4,5-dihydroimidaz-2-yl)-
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in).
vier OA license. Traditionally, imidazoline I2 sites have been characterized using
the α2-adrenoceptor antagonist [3H]-idazoxan in the presence of an
α2-adrenoceptor masking substance (Michel and Insel, 1989). How-
ever, idazoxan is also an agonist at 5-HT1A receptors which has limit-
ed the characterization of I2-imidazoline sites with this drug (Lladó et
al., 1996). Then some ligands have been developed with high selectiv-
ity for these sites, notably 2-(2-benzofuranyl)-2-imidazoline (2-BFI)
and its quinoline and isoquinoline analogs, 2-(4,5-dihydroimidaz-2-
yl)-quinoline (BU224) and 2-(4,5-dihydroimidaz-2-yl)-isoquinoline
(BU226) (Lione et al., 1998; Nutt et al., 1995). 2-BFI has been shown
to selectively label imidazoline I2 sites in mice (Anderson et al.,
2006), rabbit (Lione et al., 1996) and human brains (Wiest and
Steinberg, 1997).
There is evidence that imidazoline I2 binding sites are allosteric
sites located on monoamine oxidase (MAO) (Eglen et al., 1998;
Raddatz et al., 1997; Tesson et al., 1991), an enzyme responsible for
the oxidative deamination of neurotransmitters, like serotonin (5-hy-
droxy tryptamine, 5-HT), noradrenaline and dopamine (DA), and ex-
ogenous amines. Moreover, the abnormal function of this enzyme is
thought to be involved in several psychiatric disorders, such as de-
pression (Lanni et al., 2009; Manji et al., 2003; Millan, 2004).
Several imidazoline I2 ligands have been shown to inhibit MAO ac-
tivity (Carpéné et al., 1995; Jones et al., 2007; Raasch et al., 1999). In
16 R. Tonello et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 37 (2012) 15–21vitro experiments showed that imidazolines, including 2-BFI and
BU224, reversibly inhibit monoamine oxidase A (MAO-A) with a sim-
ilar potency to that of the reversible MAO-A inhibitor moclobemide
(Lalies et al., 1999). Furthermore, post-mortem studies have shown
that the density of I2 sites was altered in suicide/depressive patients
(García-Sevilla et al., 1996, 1998). Probably through this inhibitory
action on MAO-A, selective ligands for I2 sites may possess
antidepressant-like properties (Finn et al., 2003).
Therefore, the aim of the present study was to assess the possible
antidepressant-like effect of the 2-imidazoline derivative, 2-BFI, and
its mechanism of action in mice.
2. Materials and methods
2.1. Animals
Male Swiss mice (25–30 g) from our own colony were used in this
study. Mice were maintained in polycarbonate cages with free access
to food and water, on a 12-h alternating light–dark schedule in a
temperature-controlled (22±3 °C) room. The procedures in this
study were performed in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals and ap-
proved by the Committee on the Use and Care of Laboratory Animals
of our University (Protocol no. 119/2010). For behavioral tests, drugs
were administered in random order, and the behavioral measure was
carried out by a blinded investigator.
2.2. Drugs
2-BFI synthesis was carried out by the method of condensation in-
volving aldehydes and ethylenediamine in the presence of N-
bromosucinimide, reaching 100% purity according to analysis of 1H
nuclear magnetic resonance and 13C nuclear magnetic resonance
spectra, as previously reported (Sant'Anna et al., 2009). 2-BFI and di-
azepam (Compaz®, Cristália, Brazil) were dissolved in a vehicle solu-
tion (5% Tween 80, 20% polyethyleneglycol and 75% saline). Idazoxan,
methysergide (Sigma Chemical Co., St. Louis, USA) and haloperidol
(Haldol®, Janssen-Cilag, Brazil) were dissolved in saline. Injections
were performed in a 10 ml/kg volume by the subcutaneous (s.c.) or
intraperitoneal (i.p.) route.
2.3. Tail suspension test (TST)
The antidepressant-like effect of 2-BFI was measured using the tail
suspension test (TST), according to Steru et al. (1985). Brieﬂy, mice
were suspended by their tails using adhesive tape placed approximate-
ly 1 cm from the tip of the tail and hung approximately 30 cmabove the
table. The animals were suspended for 6 min, and the duration of im-
mobility was scored manually during the last 4-min interval of the
test. Mice were considered immobile only when they hung passively.
Firstly, a time–course curve was performed. For this, mice were
submitted to the TST at 15, 30 and 60 min after the administration
of 2-BFI (100 μmol/kg, s.c.) or the vehicle. For the dose–response
curve, mice were treated with 2-BFI (30, 100 or 300 μmol/kg, s.c.;
equivalent to 6, 19 or 56 mg/kg respectively) or vehicle 30 min before
the TST.
To assess the involvement of imidazoline sites, and serotonergic,
and dopaminergic receptors in the antidepressant-like effect of 2-
BFI, mice received a single injection of idazoxan (0.4 μmol/kg, i.p.;
equivalent to 0.1 mg/kg, a I2 site antagonist), methysergide (4 μmol/
kg, i.p.; equivalent to 2 mg/kg, a non-selective serotonergic receptor
antagonist), haloperidol (0.1 μmol/kg, i.p.; equivalent to 0.05 mg/kg,
a non-selective dopaminergic receptor antagonist) or saline 15 min
(idazoxan) or 30 min (methysergide and haloperidol) before the ad-
ministration of 2-BFI (100 μmol/kg, s.c.) or vehicle. Thirty minutes
after the treatment with 2-BFI or vehicle solution, the animals weresubmitted to the TST. All doses of antagonists used in this work
were chosen according to previous literature data (Duarte et al.,
2008; Machado et al., 2007; Rénéric et al.; 2001).
2.4. Forced swimming test (FST)
To conﬁrm the antidepressant-like effect of 2-BFI the forced swim-
ming test (FST) was used. Mice were individually forced to swim in an
open cylindrical container (diameter 10 cm, height 25 cm), contain-
ing 19 cm of water maintained at 25±1 °C; the total duration of im-
mobility during the 6-min test was scored as described previously
(Zomkowski et al., 2004). Each mouse was judged to be immobile
when it ceased struggling and remained ﬂoating motionless in the
water, making only those movements necessary to keep its head
above water. Mice were submitted to the FST 30 min after the admin-
istration of 2-BFI (100 μmol/kg, s.c.) or the vehicle.
2.5. Open-ﬁeld test (OFT)
To assess the possible effects of 2-BFI on locomotor activity, mice
were evaluated in the open-ﬁeld test (OFT), as described previously
(Archer, 1973). The number of crossings was counted in a 5-min ses-
sion. Mice were injected with 2-BFI (100 or 300 μmol/kg, s.c.) or vehi-
cle 30 min before testing. Another groups of mice were pretreated
with idazoxan (0.4 μmol/kg, i.p.), methysergide (4 μmol/kg, i.p.) or
haloperidol (0.1 μmol/kg, i.p.) 15 min (idazoxan) or 30 min (methy-
sergide and haloperidol) before the administration of vehicle or 2-
BFI (100 μmol/kg, s.c.). Thirty minutes after this treatment, the ani-
mals were submitted to the OFT.
2.6. Rota-rod test
To evaluate the effect of 2-BFI on motor coordination, the rota-rod
test was carried out (Godoy et al., 2004). The apparatus consisted of a
rotatory bar (3.7 cm in diameter) divided into 3 separate compart-
ments that was placed at a height of 25 cm and rotate at a ﬁxed veloc-
ity of 8 rpm. The animals were submitted to a training session 24 h
before testing. On the test day, mice were injected with 2-BFI (100
or 300 μmol/kg, s.c.) or vehicle 30 min before testing. Another groups
of mice were pretreated with idazoxan (0.4 μmol/kg, i.p.), methyser-
gide (4 μmol/kg, i.p.) or haloperidol (0.1 μmol/kg, i.p.) 15 min (ida-
zoxan) or 30 min (methysergide and haloperidol) before the
administration of vehicle or 2-BFI (100 μmol/kg, s.c.). Thirty minutes
after this treatment, the animals were submitted to the rota-rod
test. In the test session, the latency for the ﬁrst fall and the total num-
ber of falls were evaluated during a 4-min period.
2.7. Elevated plus maze test
The anxiety-related behaviors were assessed using the mouse ele-
vated plus maze test (Lister, 1987). The apparatus consists of two
open arms (30×5 cm) and two enclosed arms (30×5×15 cm) posi-
tioned 40 cm above the ﬂoor. The junction of four arms forms a cen-
tral square platform (5×5 cm). Mice received a single
administration of 2-BFI (100 or 300 μmol/kg, s.c.) or vehicle 30 min
before testing. As a positive control, diazepam (7 μmol/kg, s.c.; equiv-
alent to 2 mg/kg) was administered to mice 30 min before testing
(Naderi et al., 2008). Each animal was placed on the central platform
facing one of the open arms and was allowed to explore freely for 5-
min. The behavior parameters recorded were the % of number of en-
tries and the % of time spent in the open and closed arms.
2.8. Statistical analyses
The results are expressed as the mean±SEM. Student's t-test and
a one-way or two-way analysis of variance (ANOVA) were used to
Fig. 1. Effect of 2-BFI administration on immobility time in the TST and in the FST in
mice. (A) Time–course curve of 2-BFI (100 μmol/kg, s.c.) in the TST. (B) Dose–response
curve of 2-BFI (30–300 μmol/kg, s.c.) in the TST. (C) 2-BFI (100 μmol/kg, s.c.) on immo-
bility time in the FST. The values are means±SEM (n=6–8 animals in each group).
*pb0.01 compared with the respective vehicle group; two-way ANOVA followed by
Bonferroni test (A), one-way ANOVA followed by SNK (B) or Student's t-test (C).
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ferroni's or Student-Newman–Keuls' (SNK) post-hoc tests using
GraphPad Prism 5.0 software. The level of signiﬁcance was set at
pb0.05, and only signiﬁcant results are shown. To meet ANOVA as-
sumptions, haloperidol or vehicle×2-BFI or vehicle interaction data
were subjected to log transformation before statistical analysis.
3. Results
Fig. 1A shows the time–course curve of 2-BFI (100 μmol/kg, s.c.)
on immobility time in the TST. Statistical analysis (two-way
ANOVA) showed a signiﬁcant 2-BFI or vehicle×time interaction
[F(1,33)=3.52; pb0.01]. Post hoc analysis revealed a 47±7% reduc-
tion in immobility time 30 min after 2-BFI administration. Then, a 30-
min pretreatment was chosen to carry out the dose–response curve
and subsequent experiments. Fig. 1B shows the dose–response
curve of 2-BFI (30–300 μmol/kg) on immobility time in the TST. Sta-
tistical analysis (one-way ANOVA) revealed that 2-BFI decreased im-
mobility time [F(3,26)=8.43; pb0.01]. Post hoc analysis (SNK)
showed that 100 and 300 μmol/kg of 2-BFI reduced the immobility
time by 41±8% and 53±8% respectively. Fig. 1C shows that 2-BFI
(100 μmol/kg, s.c.) produced a 19±3% reduction on the immobility
time in the FST [T=4.46; pb0.01, Student's t-test].
With the purpose of investigating the mechanisms underlying the
antidepressant-like effect of 2-BFI in the TST, mice were pre-treated
with idazoxan, methysergide or haloperidol. Fig. 2A shows the effect
of pretreatment with the I2 site antagonist idazoxan (0.4 μmol/kg,
i.p.) on the reduction in the immobility time induced by 2-BFI
(100 μmol/kg). Statistical analysis (two-way ANOVA) showed a sig-
niﬁcant idazoxan or vehicle×2-BFI or vehicle interaction [(F(1,40)
=4.14; pb0.05)]. Post hoc analysis (Bonferroni's) indicated that pre-
treatment with idazoxan signiﬁcantly blocked the decrease in immo-
bility time induced by 2-BFI.
Fig. 2B shows the effect of pretreatment with the non-selective 5-
HT receptor antagonist methysergide (4 μmol/kg, i.p.) on the reduc-
tion in the immobility time induced by 2-BFI (100 μmol/kg). Statisti-
cal analysis (two-way ANOVA) showed a signiﬁcant methysergide
or vehicle×2-BFI or vehicle interaction [(F(1,31)=4.16; pb0.05)].
Post hoc analysis (Bonferroni's) indicated that pretreatment with
methysergide signiﬁcantly blocked the decrease in immobility time
induced by 2-BFI.
Fig. 2C shows the effect of the pretreatment with the non-selective
dopaminergic antagonist haloperidol (0.1 μmol/kg, i.p.) on the reduc-
tion in the immobility time induced by 2-BFI (100 μmol/kg). Statisti-
cal analysis (two-way ANOVA) revealed a signiﬁcant haloperidol or
vehicle×2-BFI or vehicle interaction [(F(1,30)=4.70; pb0.05]. Post
hoc analysis (Bonferroni's) indicated that pretreatment with haloper-
idol signiﬁcantly blocked the decrease in immobility time induced by
2-BFI.
Fig. 3 shows the effect of the classic anxiolytic benzodiazepine, diaz-
epam (7 μmol/kg, s.c.) and the effect of 2-BFI (100 and 300 μmol/kg, s.c.)
on the % of number of entries (A) and the % of time spent (B) in the open
arms of the plus-maze. Statistical analysis (one-way ANOVA) revealed
that diazepam and 2-BFI (300 μmol/kg) signiﬁcantly increased the %
of number of entries [F(3,36)=6.34; pb0.05, Fig. 3A] and the % of
time spent in the open arms [F(3,36)=10.53; pb0.01, Fig. 3B], conﬁrm-
ing the suitability of themethod used to evaluate anxiety in the present
study and suggesting an anxiolytic role for this compound. Diazepam
and 2-BFI had no effect on the % of number of entries and the % of
time spent in the closed arms (data not shown).
It has been found that compounds that induce changes in locomo-
tor activity can alter the behavioral responses of mice in the TST.
Therefore, we investigated the effects of 2-BFI alone and in combina-
tion with idazoxan, methysergide or haloperidol on locomotor activ-
ity and motor coordination function. The results are shown in Table 1.
The treatment with 2-BFI (100 and 300 μmol/kg, s.c.) did not causesigniﬁcant alterations in the locomotor ability of the animals, as
assessed by the similar number of crossings in the OFT when com-
pared to vehicle. The co-treatment of mice with 2-BFI and idazoxan
(0.4 μmol/kg, i.p.), methysergide (4 μmol/kg, i.p.) or haloperidol
(0.1 μmol/kg, i.p.) causes no changes on locomotor activity, when
compared to saline plus vehicle treated animals. In addition, 2-BFI
alone or in combination with antagonists did not signiﬁcantly affect
motor coordination, as assessed by similar fall latencies and total
number of falls in the rota-rod when compared to control groups.
4. Discussion
In the present study, subcutaneous injection of 2-BFI, a 2-
imidazoline derivative, decreased the immobility time in the TST,
Fig. 2. Effect of pretreatment of mice with idazoxan (0.4 μmol/kg, i.p.; A), methysergide
(4 μmol/kg, i.p.; B) and haloperidol (0.1 μmol/kg, i.p.; C) on the anti-immobility effect
of 2-BFI (100 μmol/kg, s.c.) in the TST. The values are means±SEM (n=7–11 animals
in each group). *pb0.05 compared with the vehicle group; two-way ANOVA followed
by Bonferroni test.
Fig. 3. Effects of diazepam (7 μmol/kg, s.c.), 2-BFI (100 and 300 μmol/kg, s.c.) or vehicle
on the % of number of entries (A) and the % of time spent (B) in the open arms by mice
submitted to a 5-min test in the elevated plus maze. The values are means±SEM
(n=10 animals in each group). *pb0.05 or **pb0.01 compared with the vehicle
group; one-way ANOVA followed by SNK.
Table 1
Effects of vehicle or 2-BFI (100 or 300 μmol/kg, s.c.) treatment and 2-BFI (100 μmol/kg,
s.c.) plus idazoxan (0.4 μmol/kg, i.p.), methysergide (4 μmol/kg, i.p.) or haloperidol
(0.1 μmol/kg, i.p.) co-treatment on the number of crossing in open-ﬁeld test and fall la-
tency and number of falls in rota-rod test in mice.
Treatment (μmol/kg) Number of
crossing
Fall latency (s) Number
of falls
Vehicle 28.4±3.9 190.8±26.3 0.5±0.3
2-BFI (100) 33.0±6.0 142.5±28.9 1.4±0.6
2-BFI (300) 24.5±3.2 221.6±18.4 0.1±0.1
Saline+vehicle 44.0±8.9 222.5±17.5 0.2±0.2
Idazoxan+vehicle 34.8±4.6 193.8±30.7 0.3±0.2
Methysergide+vehicle 50.3±6.0 210.2±27.7 0.8±0.6
Haloperidol+vehicle 40.8±6.8 207.8±32.2 0.3±0.3
Idazoxan+2-BFI (100) 37.3±4.5 166.8±34.5 0.8±0.5
Methysergide+2-BFI (100) 30.2±5.3 188.2±34.0 0.5±0.3
Haloperidol+2-BFI (100) 29.0±4.8 201.2±28.6 1.0±0.7
The values are mean±SEM of 6–10 animals in each group (rota-rod test) and 6–7
animals in each group (open-ﬁeld test).
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ﬂicting on the antidepressant-like potential of imidazoline com-
pounds. O'Neill et al. (2001) demonstrated that selective I2
receptor ligands (such as BU224) do not show antidepressant-like
effects in the FST in BKTO mice. However, Taksande et al. (2009)
showed that I2 receptor ligands (including 2-BFI) were effective in
reducing the immobility time in the FST and in potentiating
antidepressant-like effects on selective 5-HT reuptake inhibitors in
Swiss mice. The differences between these studies may be explained
by the differences among I2 receptor ligands, the test used to detect
the antidepressant-like effects and the strain of mice used. 2-BFI, but
not BU224, binds with low afﬁnity to α2-adrenoceptors (Eglen et al.,
1998). Accordingly, the nature the interaction between the 2-BFI to
α2-adrenoceptors is still uncertain. Of note, α2-adrenoceptors an-
tagonists have antidepressant-like effects (Haddjeri et al., 1995). In-
deed, mirtazapine, a highly potent α2-adrenoceptor antagonist, is
effect in the treatment of patients with depression (De Boer,
1996). In addition, an increased level of α2-adrenoceptors (31–40%) was found in the prefrontal cortex of depressed patient
(García-Sevilla et al., 1999). Then, if the 2-BFI is interacting as an
α2-adrenoceptors antagonist, this propriety may, at least in part, ex-
plain its effect.
Regarding the test, the TST is the most common animal test specif-
ically used for the screening of new antidepressant drugs because it is
easy to execute and highly reliable (Bourin et al., 2005; Cryan et al.,
2002). In this test, mice are exposed to an aversive situation, from
which there is no escape, and will, after periods of agitation, cease
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observed in the FST (Porsolt et al., 1977; Steru et al., 1985). Perhaps
one of the most important differences between these tests is the ap-
parent higher sensitivity of the TST in detecting the response to
drugs (Cryan et al., 2005). Thus, the better sensitivity of the TST
may facilitate the detection of the antidepressant-like effects of I2 re-
ceptor ligands. Finally, there is an important difference in the re-
sponse to antidepressants between mouse strains, but Swiss mice
are most commonly used because they exhibit increased responses
to these drugs (Bourin et al., 2005). As Taksande et al. (2009), the pre-
sent study used Swiss mice, which may improve the assessment of
the antidepressant-like effects of 2-BFI.
Conﬁrming the results found in TST, 2-BFI decreased the immobil-
ity time in the FST. In accordance with Taksande et al. (2009), that
showed that 2-BFI and others I2 receptor ligands were effective in re-
ducing the immobility time in the FST. Similar to 2-BFI, agmatine, an
endogenous ligand at I1 and I2 receptors, presented antidepressant
and anxiolytic activity in rodents (Aricioglu and Altunbas, 2003;
Zomkowski et al., 2002). Of note, agmatine displaced the binding of
[3H]2-BFI to I2-imidazoline receptors (Alemany et al., 1997). In addi-
tion, the catabolism of agmatine by agmatinase has recently been
found to be increased in post-mortem brains of patients with uni-
and bipolar disorder (Bernstein et al., 2012). Thus, with the putative
reduction of the endogenous ligand, the use of synthetic I2 receptor li-
gands, such as 2-BFI, could be useful in this illness.
Clinical depression in humans is associated with dysregulation or
overexpression of imidazoline sites in platelets and brain tissues of
depressed patients (García-Sevilla et al., 1999; Holt, 2003; Piletz et
al., 2008). Considering that these sites have a role in mood disorders,
the involvement of the imidazoline sites in the antidepressant-like ef-
fect of 2-BFI in the TST was studied by using an I2 antagonist to exam-
ine the behavioral responses to 2-BFI (García-Sevilla et al., 1999;
Piletz et al., 1996). Our study showed that the reduction in the immo-
bility time elicited by 2-BFI in the TST was blocked by pretreatment of
mice with idazoxan, a preferential imidazoline I2 receptor antagonist,
suggesting the involvement of imidazoline I2 receptors in the
antidepressant-like effect of 2-BFI. Some studies have shown that ida-
zoxan prevented the antidepressant-like effect of desipramine, a nor-
adrenaline reuptake inhibitor, in the FST (Cervo et al., 1990; Rénéric
et al., 2001). Agreeing with the involvement of 2-BFI with imidazoline
I2 receptors, previous studies reporting that [3H]2-BFI bound with
higher afﬁnity than [3H]idazoxan, an α2-adrenoceptors antagonist
traditionally used to characterize I2-imidazoline receptors, to a simi-
lar number of brain I2-imidazoline receptors (Alemany et al., 1997).
An enzyme that causes oxidative deamination of neurotransmit-
ters like 5-HT, noradrenaline, DA and exogenous amines is the MAO.
For decades, the notion that perturbed monoaminergic transmission
is causally implicated in depressive states has been enshrined in the
literature (Manji et al., 2003). There is evidence that imidazoline I2
binding sites are located in MAO (Eglen et al., 1998; Raddatz et al.,
1997; Tesson et al., 1991), and that 2-BFI can inhibit MAO activity in
a non-competitive manner (Carpéné et al., 1995). It was recently
shown that 2-imidazoline derivatives showed good potency and se-
lectivity in inhibiting the in vitro activity of MAO in the rat brain
(Sant'Anna et al., 2009). Among these compounds, 2-BFI showed a
great potency to reversibly inhibit the in vitro activity of MAO-A
(Lalies et al., 1999; Sant'Anna et al., 2009). Thus, the antidepressant-
like action of 2-BFI could be related to the monoaminergic system
owing to its inhibitory effect on MAO activity.
Besides the interaction with imidazoline I2 site, imidazol(ine) li-
gands can interact with DA receptors. Sastre-Colla et al. (2001) dem-
onstrated that 2-BFI presents very low afﬁnity for D2-dopamine
receptors in vitro. However until now, do not have any study showing
the afﬁnity of 2-BFI to 5-HT receptors.
It is well known that the 5-HT system plays an important role in
the neural regulation of mood (Duman et al., 1997). Theantidepressant drugs used clinically promote an increase in 5-HT
and noradrenaline availability at the synaptic cleft (Elhwuegi,
2004). Some studies have shown the involvement of 5-HT receptors
in depression (Pitchot et al., 2005; Svenningsson et al., 2006). In the
present study, we also investigated the involvement of the serotoner-
gic and dopaminergic systems on the antidepressant-like effect of 2-
BFI in the TST. The decrease in the immobility time elicited by 2-BFI
was reversed by pretreatment of mice with methysergide, a non-
selective serotonin receptor antagonist. In the same way, the results
demonstrated that haloperidol, a non–selective DA receptor antago-
nist, signiﬁcantly antagonized the anti-immobility effect of 2-BFI in
mice. These results indicate that the antidepressant-like effect pro-
duced by 2-BFI may also involve the serotonergic and dopaminergic
systems.
It has been shown that the effects of some antidepressants are
prevented by the concurrent administration of a 5-HT1A receptor an-
tagonist (Detke et al., 1995). Also, there was a signiﬁcant hypersensi-
tivity of 5-HT2 receptors in the brains of depressed suicide victims
(Rosel et al., 2000).
Depressed patients have been reported to have increased DA D1/
D2 receptor binding (Shah et al., 1997) and reduced DA transporter
activity (Neumeister et al., 2001). Pharmacological experiments sug-
gest that the DA-like receptors play a key role in the response to bio-
logical antidepressant treatments (Lammers et al., 2000; Maj et al.,
1996; Rogoz and Dziedzicka-Wasylevska, 1999).
Some studies have demonstrated that antidepressant agents, in-
cluding the MAOIs, can also possess anxiolytic properties in different
anxiety animal models (De Angelis, 1996; Eroğlu and Güven, 1998).
Thus, to investigate if 2-BFI exerts anxiolytic activity, mice were sub-
mitted to the plus maze test, and the results showed that 2-BFI
(300 μmol/kg) was able to signiﬁcantly increase the % of number of
entries and the % of time spent in the open arms. These data suggest
that 2-BFI, besides producing antidepressant-like effects, may present
anxiolytic properties in high doses.
The anti-immobility effect of 2-BFI seems unassociated with alter-
ations on locomotor activity, since mice treated with 2-BFI at doses
that were effective in the TST (100 and 300 μmol/kg) did not exhibit
increased ambulation when tested in the OFT. The effect of 2-BFI on
coordination function was also evaluated using the rota-rod test. No
changes in motor coordination activity 30 min after 2-BFI treatment
were observed in both 100 and 300 μmol/kg doses. This indicates
that a psychostimulant effect is not responsible for the decrease in
the immobility elicited by 2-BFI in the TST.
5. Conclusion
In conclusion, the present results show that 2-BFI presents antide-
pressant-like effects in mice in both TST and FST. The 2-BFI
antidepressant-like effect is reversed by pretreatment with idazoxan,
methysergide and haloperidol, suggesting a relationship to the sero-
tonergic, dopaminergic and imidazoline (I2 receptors) systems. Fur-
ther studies using other selective or highly speciﬁc analytical and
pharmacological tools are needed to more reasonably deﬁne the
role of serotonergic, dopaminergic and imidazoline systems in the
antidepressant-like effects of 2-BFI.
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